53 related articles for article (PubMed ID: 38691651)
1. Opdualag for metastatic melanoma.
Med Lett Drugs Ther; 2023 Jan; 65(1668):e19-e20. PubMed ID: 36651796
[No Abstract] [Full Text] [Related]
2. A systematic literature review and network meta-analysis of effectiveness and safety outcomes in advanced melanoma.
Franken MG; Leeneman B; Gheorghe M; Uyl-de Groot CA; Haanen JBAG; van Baal PHM
Eur J Cancer; 2019 Dec; 123():58-71. PubMed ID: 31670077
[TBL] [Abstract][Full Text] [Related]
3. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF.
Dummer R; Flaherty KT; Robert C; Arance A; B de Groot JW; Garbe C; Gogas HJ; Gutzmer R; Krajsová I; Liszkay G; Loquai C; Mandalà M; Schadendorf D; Yamazaki N; Pietro AD; Cantey-Kiser J; Edwards M; Ascierto PA
Future Oncol; 2023 May; 19(16):1091-1098. PubMed ID: 37309702
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma.
Li SN; Wan X; Peng LB; Li YM; Li JH
BMC Health Serv Res; 2023 Jan; 23(1):49. PubMed ID: 36653848
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
[TBL] [Abstract][Full Text] [Related]
6. Lifileucel (Amtagvi): A cellular therapy for melanoma.
Med Lett Drugs Ther; 2024 Apr; 66(1701):e77-e78. PubMed ID: 38691651
[No Abstract] [Full Text] [Related]
7. Melanoma: An update on systemic therapies.
Skudalski L; Waldman R; Kerr PE; Grant-Kels JM
J Am Acad Dermatol; 2022 Mar; 86(3):515-524. PubMed ID: 34915056
[TBL] [Abstract][Full Text] [Related]
8. Advances in the systemic treatment of metastatic melanoma.
Yushak M; Kluger HM; Sznol M
Oncology (Williston Park); 2013 May; 27(5):374-81. PubMed ID: 25184258
[TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of targeted therapies for BRAF-mutant unresectable or metastatic melanoma: Results from a systematic literature review and a network meta-analysis.
Corrie P; Meyer N; Berardi R; Guidoboni M; Schlueter M; Kolovos S; Macabeo B; Trouiller JB; Laramée P
Cancer Treat Rev; 2022 Nov; 110():102463. PubMed ID: 36099854
[TBL] [Abstract][Full Text] [Related]
10. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
Trojaniello C; Festino L; Vanella V; Ascierto PA
Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
[TBL] [Abstract][Full Text] [Related]
11. The Role of BRAF-Targeted Therapy for Advanced Melanoma in the Immunotherapy Era.
Vanella V; Festino L; Trojaniello C; Vitale MG; Sorrentino A; Paone M; Ascierto PA
Curr Oncol Rep; 2019 Jul; 21(9):76. PubMed ID: 31359162
[TBL] [Abstract][Full Text] [Related]
12. Current and future roles of targeted therapy and immunotherapy in advanced melanoma.
Olszanski AJ
J Manag Care Spec Pharm; 2014 Apr; 20(4):346-56. PubMed ID: 24684639
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
